Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Deloitte
McKinsey
Federal Trade Commission
Harvard Business School
Julphar
Colorcon
Fuji

Generated: January 19, 2019

DrugPatentWatch Database Preview

Alemtuzumab - Biologic Drug Details

« Back to Dashboard

Summary for alemtuzumab
Tradenames:2
Patents:303
Applicants:1
BLAs:1
Suppliers: see list1
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for alemtuzumab
Pharmacology for alemtuzumab

US Patents for alemtuzumab

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07 ➤ Try a Free Trial SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) ➤ Try a Free Trial RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07 ➤ Try a Free Trial IBC Pharmaceuticals, Inc. (Morris Plains, NJ) ➤ Try a Free Trial RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07 ➤ Try a Free Trial University of Georgia Research Foundation, Inc. (Athens, GA) ➤ Try a Free Trial RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07 ➤ Try a Free Trial AbbVie Stemcentrx LLC (North Chicago, IL) ➤ Try a Free Trial RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07 ➤ Try a Free Trial University of the Sciences of Philadelphia (Philadelphia, PA) ➤ Try a Free Trial RX Orphan search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for alemtuzumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015000061 Germany ➤ Try a Free Trial PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
199051 Germany ➤ Try a Free Trial PRODUCT NAME: MABCAMPATH-ALEMTUZUMAB IN ALLEN SEINEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/01/193/001 20010706
2016 00031 Denmark ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326
/2001 Austria ➤ Try a Free Trial PRODUCT NAME: ALEMTUZUMAB; REGISTRATION NO/DATE: EU/1/01/193/001 20010706
0067 Netherlands ➤ Try a Free Trial PRODUCT NAME: ALEMTUZUMAB; REGISTRATION NO/DATE: EU/1/01/193/001 20010706
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
UBS
Queensland Health
Baxter
Cipla
Teva
US Army
Fish and Richardson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.